London: Monday, January 16, 2017: Hutchison China MediTech Limited today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa in the first-line setting for patients with advanced or metastatic non-small cell lung cancer in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors .